Receive our newsletter – data, insights and analysis delivered to you
July 22, 2009

UK Recommends Rituximab as First-Line Treatment for Chronic Leukaemia

The UK National Institute for Health and Clinical Excellence (NICE) has recommended that rituximab should be considered as a possible first-line treatment for people with chronic lymphocytic leukaemia. NICE recommends that rituximab be used only by patients who are able to take fludarabin

By cms admin

The UK National Institute for Health and Clinical Excellence (NICE) has recommended that rituximab should be considered as a possible first-line treatment for people with chronic lymphocytic leukaemia.

NICE recommends that rituximab be used only by patients who are able to take fludarabine in combination with cyclophosphamide. Rituximab is not recommended in combination with any other chemotherapy agents.

NICE Health Technology Evaluation Centre director Dr Carole Longson said that after looking at all of the available evidence the independent Appraisal Committee concluded that rituximab represented an effective use of NHS resources.

“This important guidance increases the treatment options available to people with this condition, wherever they live in England and Wales,” Longson said.

Chronic lymphocytic leukaemia, a cancer that affects white blood cells, is the most common form of adult leukaemia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU